** Shares of therapy developer Prothena Corporation PRTA.O are down nearly 2% at $4.77 in pre-market trading
** Jefferies downgrades the stock's rating to "hold" from "buy"; slashes PT to $6 from $32, a 8.8% discount to the last close
** PRTA becomes stock with lowest PT, per Jefferies, on Wall Street
** We see uncertainty around the pipeline given the failure of the AL amyloidosis (a disease where abnormal proteins damage organs) drug - brokerage
** Adds it finds "risk" in the co's Alzheimer's drug PRX012 phase 1 trial data
** Co says phase 3 clinical trial of Birtamimab in patients with AL amyloidosis did not meet primary endpoint
** Avg rating of 10 analysts is "buy"; median PT $29.5— data compiled by LSEG
** PRTA falls ~52.49% YTD, up to last close
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.